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Clifford S. Deutschman, MD; Derek C. Angus, MD, MPh; Gordon D. Rubenfeld, MD, MSc; Mervyn Singer, MD, FRCP; for the Sepsis Definitions Task Force
IMPORTANCE Septic shock currently refers to a state of acute circulatory failure associated
with infection. Emerging biological insights and reported variation in epidemiology challenge
the validity of this definition.
OBJECTIVE Todevelop anewdefinition andclinical criteria for identifying septic shock in adults.
DESIGN, SETTING, AND PARTICIPANTS The Society of Critical CareMedicine and the European
Society of Intensive Care Medicine convened a task force (19 participants) to revise current
sepsis/septic shock definitions. Three sets of studies were conducted: (1) a systematic review
andmeta-analysis of observational studies in adults published between January 1, 1992, and
December 25, 2015, to determine clinical criteria currently reported to identify septic shock
and inform the Delphi process; (2) a Delphi study among the task force comprising 3 surveys
and discussions of results from the systematic review, surveys, and cohort studies to achieve
consensus on a new septic shock definition and clinical criteria; and (3) cohort studies to test
variables identified by the Delphi process using Surviving Sepsis Campaign (SSC)
(2005-2010; n = 28 150), University of PittsburghMedical Center (UPMC) (2010-2012;
n = 1 309025), and Kaiser Permanente Northern California (KPNC) (2009-2013;
n = 1 847 165) electronic health record (EHR) data sets.
MAIN OUTCOMES ANDMEASURES Evidence for and agreement on septic shock definitions
and criteria.
RESULTS The systematic review identified44 studies reporting septic shockoutcomes (total of
166479patients) froma total of 92 sepsis epidemiology studies reportingdifferent cutoffs
and combinations for bloodpressure (BP), fluid resuscitation, vasopressors, serum lactate level,
andbasedeficit to identify septic shock. The septic shock–associated crudemortalitywas46.5%
(95%CI, 42.7%-50.3%),with significant between-study statistical heterogeneity (I2 = 99.5%;
τ2 = 182.5;P < .001). TheDelphi process identifiedhypotension, serum lactate level,
andvasopressor therapy as variables to test using cohort studies. Basedon these3variables
aloneor in combination, 6patient groupsweregenerated. Examinationof theSSCdatabase
demonstrated that thepatient group requiring vasopressors tomaintainmeanBP65mmHg
or greater andhaving a serum lactate level greater than2mmol/L (18mg/dL) after fluid
resuscitationhada significantly highermortality (42.3%[95%CI, 41.2%-43.3%]) in risk-adjusted
comparisonswith theother 5 groupsderivedusingeither serum lactate level greater than
2mmol/L aloneor combinationsof hypotension, vasopressors, and serum lactate level 2mmol/L
or lower. These findingswere validated in theUPMCandKPNCdata sets.
CONCLUSIONSANDRELEVANCE Basedona consensusprocess using results froma systematic
review, surveys, and cohort studies, septic shock is definedas a subset of sepsis inwhich
underlying circulatory, cellular, andmetabolic abnormalities are associatedwith agreater risk of
mortality than sepsis alone.Adult patientswith septic shock canbe identifiedusing the clinical
criteria of hypotension requiring vasopressor therapy tomaintainmeanBP65mmHgor greater
andhaving a serum lactate level greater than2mmol/L after adequate fluid resuscitation.
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C onsensusdefinitions, generated in 19911 andrevisited in2001,2 describe septic shock as a state of cardiovascu-lar dysfunction associated with infection and unex-
plainedbyothercauses.The increasingavailabilityof largeelec-
tronichealthrecord(EHR)datasets, registries,nationalcasemix
programs, trial data sets, and claims databases using Interna-
tionalClassificationofDiseasescodeshavesincegeneratedmul-
tiple observational studies reporting septic shock epidemiol-
ogy. However, variable interpretation and application of the
consensus definitions1,2 have contributed to variable esti-
mates of both incidence and outcomes.3-8 It is unclear towhat
extent thesevariations represent truedifferencesor anartifact
attributable to inconsistentuseof definitions.8,9 Furthermore,
emerging insights intosepsispathophysiology10-13warranta re-
viewof thecurrent septic shockdefinitionand thecriteriaused
to identify it clinically.
Against this background, the Society of Critical CareMedi-
cine (SCCM) and the European Society of Intensive Care Med
(ESICM) convened an international task force to reviewdefini-
tionsof sepsis andseptic shock in January2014.Tosupport the
task force deliberations on redefining septic shock, a series of
activities was performed: a systematic review and meta-
analysis of criteriaused inobservational studies reporting sep-
sis epidemiology in adults; a Delphi study to achieve consen-
sus; cohort studies using the Surviving Sepsis Campaign (SSC)
registry; and subsequent testingof the applicability of thenew
criteria in patients with suspected infection from 2 large EHR-
deriveddata sets.Theaimsof this studywere todevelopanup-
dated septic shock definition and to derive clinical criteria for
identifyingpatientswithsepticshockmeetingthisupdateddefi-
nition.Specifically, thisupdateddefinitionandthesecriteriaare
intended to provide a standard classification to facilitate clini-
cal care, future clinical research, and reporting.
Methods
In thisarticle, “definition”refers toadescriptionofseptic shock
and “clinical criteria” to variables used to identify adult pa-
tients with septic shock.
Task Force
TheSCCMandESICMeachnominatedcochairsof the task force
andprovidedunrestrictedfundingsupporttowardtheworkcon-
ducted.The2cochairs thenselected 17other task forcepartici-
pants based on their scientific expertise in sepsis epidemiol-
ogy,clinical trials, andbasicor translational research.Task force
participants are listed at the end of the article. The task force
retainedcompleteautonomyforalldecisions.ESICMandSCCM
hadno role in studydesign, conduct, or analysis butwere con-
sulted for peer review and endorsement of themanuscript.14
Systematic Review andMeta-analysis
The aims of the systematic review were to assess the differ-
ent criteria used to identify adult patients with septic shock
andwhether these criteriawere associatedwithdifferences in
reported outcomes. MEDLINE was searched using search
terms,MeSHheadings,andcombinationsof sepsis, septic shock,
and epidemiology and limits of human studies; adults 19 years
or older; English-languagepublications; andpublicationdates
between January 1, 1992 (1991definitions1), andDecember 25,
2015. For full-text review, only noninterventional studies re-
porting sepsis epidemiology and all-cause mortality were in-
cluded.Randomizedclinical trialswere excluded, because the
additional inclusionandexclusioncriteriamight confound the
effect of criteria onmortality (the study objective).8 To avoid
variability in outcomes related to specific pathogens, specific
patient groups, and interventional before-and-after studies,
studies reporting these populationswere also excluded. Data
were extracted on cohort recruitment period, cohort charac-
teristics, setting,criteriausedto identifysepticshock,andacute
mortality.Detailedmethods, includingsearchstrategy, arepre-
sented in eMethods 1 and eTable 1 in the Supplement.
Delphi Study
To generate consensus on the septic shock definition and cri-
teria, 3 face-to-face meetings, 3-round sequential pretested
questionnaires,andemaildiscussionsamongthetaskforcepar-
ticipantswere conducted.One task forcememberdidnot par-
ticipate in these surveys because of lack of content expertise,
and1didnot respondtothefirst2surveys.Questionnaireswere
developed, refined, andadministeredconsistingof single- and
multiple-answerquestions, free-text comments, anda5-point
Likert agreement scale. For consensus discussions and not-
ing agreement, the 5-point Likert agreement scales were
grouped at the tails of the scale choices (ie, “strongly dis-
agree”groupedwith“disagree”; “stronglyagree”groupedwith
“agree”).All outputs fromthe systematic review, surveys, and
the results of cohort studies were made available to partici-
pants throughout the Delphi study.
In the first round (August 2014), using 26 questions in 4
domains, agreement and opinions were explored on (1) com-
ponents of the new septic shock definition; (2) variables and
their cutoffs identified by the systematic review; (3) defini-
tions of, and criteria for, hypotension, persistent hypoten-
sion, adequacyof resuscitation, and resuscitation endpoints;
and (4) septic shock severity scoring. In the second round
(November 2014), 4 questions were used to generate state-
ments for key terms (persistent hypotension, adequacy of re-
suscitation, and septic shock) and to reach agreement on test
variables and outcomes for subsequent analysis of predictive
validity. Theobjectives of the third round (January2015)were
to establish a consensus definition of septic shock and re-
lated clinical criteria. In the third survey, the task forcemem-
bers were given 4 choices for the septic shock updated crite-
ria ([1] serum lactate level alone; [2] hypotension alone;
[3] vasopressor-dependent hypotension or serum lactate
level; [4] vasopressor-dependenthypotension and serum lac-
tate level) and were asked to provide their first and second
choices. The cumulative first or second choices were used to
agree on the reported septic shock criteria.
Questionnaire items were accepted if agreement ex-
ceeded 65%. Choices for which agreement was less than 65%
were rediscussed to achieve consensus orwere eliminated, as
appropriate to achieve theproject aims. The surveyquestion-
naires are presented in eMethods 2 in the Supplement.
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Cohort Studies
The institutional review boards of Cooper University Hospital
(Camden,NewJersey),15UniversityofPiitsburghMedicalCen-
ter (UPMC; a network of hospitals in western Pennsylvania),
and Kaiser Permanente Northern California (KPNC)16 pro-
videdethics approvals for researchusing theSSCandEHRdata
sets, respectively.
The SSC registry includes data collected from 218 hospi-
tals in 18 countries on 28 150 patients with suspected infec-
tion who, despite adequate fluid resuscitation as judged by
the collecting sites, still had 2 or more systemic inflamma-
tory response syndrome criteria and 1 ormore organdysfunc-
tion criteria (eMethods 3 in the Supplement). The SSC data-
base setup, inclusion, and reporting items are described in
detail elsewhere.6,17 To select clinical criteria for thenewsep-
tic shock definition, an analysis data set was created that in-
cluded all patientswith a serum lactate levelmeasurement or
ameanarterialpressure less than65mmHgafter fluids,orwho
received vasopressors.
Forexternalvalidation,mortalitywasdeterminedusingthe
same clinical criteria in patients with suspected infection
(cultures taken,antibiotics commenced)within2 largeEHRda-
tabases fromUPMC(12hospitals,2010-2012,n = 1309025)and
KPNC (20hospitals, 2009-2013, n = 1847 165). Threevariables
(hypotension, highest serum lactate level, and vasopressor
therapyasabinaryvariable [yes/no])wereextracted fromthese
2 data sets during the 24-hour period after infection was sus-
pected.Descriptiveanalyses, similar to thoseperformedonthe
SSC data set, were then undertaken. Because of constraints on
data availability, hypotension was considered present if sys-
tolic bloodpressurewas 100mmHgor less for any singlemea-
surement taken during the 24-hour period after infection was
suspected. Serum lactate levels were measured in 9% of in-
fectedpatientsatUPMCandin57%ofthoseatKPNCafter imple-
mentation of a sepsis quality improvement program.
Statistics
Meta-analysis
A random effects meta-analysis of septic shock mortality by
study-specific septic shock criteria and sepsis definitionswas
performed.Twometa-regressionmodels of septic shockmor-
talitywere testedwith the covariates: sepsis definition, crite-
ria for shock,mid–cohort-year of studypopulation, single cen-
ter or multicenter, and World Health Organization member
state regions.18 These 2 models (with and without per capita
intensive care unit beds) were generated to account for inter-
national cohorts and countries for which per capita intensive
care unit bed data were unavailable (See eMethods 1 in the
Supplement for details).
Cohort Studies
Hospital mortality was used as the primary outcome for deri-
vationanddescriptivevalidationanalysis.Using the3dichoto-
mousvariables identified in round2of theDelphi process, the
SSC cohortwas divided into 6 groups and the variables tested
either alone or in combination: (1) hypotension (mean arte-
rial pressure <65mmHg) after fluid administration; (2) vaso-
pressor therapy; and (3) serum lactate level greater than
2 mmol/L or 2 mmol/L or less (to convert serum lactate val-
ues tomg/dL,divideby0.111).Hypotensionwasassumedwhen
vasopressor therapywasbeingadministered, generating6dis-
tinct potential septic shock patient groups using the 3 se-
lected variables (eTable 5 in the Supplement). Analyses were
performedusingeither the6groupsor the3dichotomousvari-
ables as the risk factor. Subsequent analyses using the serum
lactate level as a categorical variable were performed using a
χ2 test of trend for mortality.
Currently, therearenogoldstandardsepticshockcriteria for
predictivevaliditycomparisons.8Thus, theseanalysesaimedto
identifyapatientpopulationthathas theattributesof thenewly
proposeddefinition,which includeshighermortalitycompared
withotherpatientpopulationscommonlyreportedashavingsep-
tic shock in the literature identified by the systematic review.
Therefore, the independent relationship between the 3 poten-
tial criterionvariables (hypotension,serumlactate level,andva-
sopressortherapy)agreedonthesecondroundoftheDelphipro-
cessanda futureoutcome (hospitalmortality)was testedusing
Figure 1. Study Identification and Selection Process Used
in the Systematic Review
1017 Records identified and screened
982 MEDLINE
35 Other sources a
102 Met full-text review criteria
915 Excluded
894 Did not meet screening
criteria
21 Duplicate
26 New records included from
reference search of full-text
articles
92 Included for qualitative synthesis
of definitions and criteria
44 Reported septic shock–specific mortality
for quantitative synthesis c
36 Excluded b
16 Specific population
10 Included all age groups
10 Interventional study
a Nonduplicate references from other sources included review articles.3,108-110
See eMethods 1 in the Supplement for further details of search strategy.
bRefers to records that were excluded after reference screening of full text
articles. The screening criteria for full text inclusion were reporting of all case
sepsis epidemiology in adult populations without specific assessment of
interventions. The qualitative review assessed sepsis and septic shock
definitions and criteria. The records included in the qualitative review
(92 studies5-7,19-107) are presented in eTable 2 in the Supplement. The
quantitative review assessed septic shock criteria andmortality.
c Refers to the records included for quantitative assessment of septic shock
mortality and the heterogeneity by criteria using random-effects
meta-analysis (44 studies5-7,19-59) (eTable 2 in the Supplement).
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2generalizedestimatingequationpopulation-averaged logistic
regression models with exchangeable correlation structure,
where hospital sitewas the panel variable.
The firstmodel used the potential septic shock groups 1 to
6derivedfromthesevariables(eTable5intheSupplement),with
group 1 as the referent group and adjusted for other covariates
toassesstruemortalitydifferencebetweenthesegroups.Thesec-
ondmodel assessed the independent associationof these3po-
tentialcriterionvariablesonhospitalmortalityadjustedforother
covariates. Thesemodels also included an a priori adjustment
variable for covariates including region (United States and
Europe), locationwhere sepsis was suspected (emergency de-
partment,ward,or critical careunit), antibiotic administration,
steroiduse, organdysfunction (pulmonary, renal, hepatic, and
acutelyalteredmental state), infectionsource (pneumonia,uri-
nary tract infection, abdominal, meningitis and other), hyper-
Table 1. Summary of Septic Shock Definitions and Criteria Reported in the Studies Identified by the Systematic Reviewa
Criteria
Septic Shock Case Definitions and Corresponding Variables Reported in Literature
Other Description
of Criteria Variables
Consensus Definitions Other Definitions
Bone et al1 Levy et al2 SSC111 Trial-based112
Infection Suspected or proven Suspected or proven Suspected or proven Suspected or proven Bacteremia, culture
positive; CDC definitions
for infection
SIRS criteria, No. 2 One or more of 24
variablesb
2 3 NA
Septic shock
description
Sepsis-induced
hypotension despite
adequate resuscitation
OR receiving
vasopressors/Inotropes
plus presence of
perfusion abnormalities
State of acute circulatory
failure characterized
by persistent arterial
hypotension after
adequate resuscitation
unexplained by
other causes
Sepsis-induced
hypotension persisting
despite adequate
fluid resuscitation
Cardiovascular
dysfunction defined as
hypotension despite
adequate resuscitation
or need for vasopressors
Precoded data using
ICD-9 and ICD-10 codesc
Hypotension, mm Hg
Systolic BP <90 <90 <90 <90 <100
Decrease
in systolic BP
Decrease >40 Decrease >40 Decrease >40 NA<70 >50% decrease in
hypertension
MAP No <60 <70 Hypotension lasting
>1 h after resuscitation
<65
Adequate resuscitation
definition
Not defined Not defined Goals set as CVP
8-12 mm Hg; urine
output ≥0.5 mL/kg/h;
ScvO2 >70%
Not defined After resuscitation fluids
(0.5 L; 1 L; 1.5 L;
20 mL/kg ideal
body weight
Vasopressor use Yes (not absolute
requirement)
Yes (CVS SOFA score) Yes (not absolute
requirement)
Yes (not absolute
requirement)
Vasoactive drugs required
for >30 min
Hypoperfusion
abnormalities
Hypoperfusion
abnormality defined as
lactic acidosis; oliguria;
low Glasgow Coma Score
Tissue hypoperfusion
defined as serum lactate
>1 mmol/L or delayed
capillary refill
Tissue hypoperfusion
defined as
infection-induced
hypotension, elevated
serum lactate
(>4 mmol/L), or oliguria
No description Serum lactate
>2.5 mmol/L; base deficit
>5 mEq/L, alkaline
reserve <18 mEq/L;
CVP <8; PCWP <12
Data points from
included studies,
No. (%)d
39 (75) 13 (25)
Sample size, No. 158 354 8125
Mortality by septic
shock definition using
random-effects meta
analysis, % (95% CI)
47.2 (42.7-51.7) 44.2 (38.5-49.9)
I2, %e 99.6 95.9
τ2f 191.21 94.9
P value heterogeneity <.001 <.001
Abbreviations: BP, blood pressure; CDC, Centers for Disease Control and
Prevention; CVP, central venous pressure; CVS, cardiovascular system;
ICD, International Classification of Diseases; MAP, mean arterial pressure;
NA, not applicable; PCWP, pulmonary capillary wedge pressure; SBP, systolic
blood pressure; ScvO2, central venous oxygen saturation; SIRS, systemic
inflammatory response syndrome; SOFA, Sequential [Sepsis-related] Organ
Failure Assessment; SSC, Surviving Sepsis Campaign.
SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.
a The summary table was generated from eTable 2 data from 92 studies.5-7,19-107
b Levy et al highlight an extended variable list as a replacement for SIRS criteria
consisting of general (n = 7); inflammatory (n = 5); hemodynamic (n = 3);
organ dysfunction (n = 7) and tissue perfusion (n = 2) variables.2
c Different ICD-9 codes are reported to identify septic shock in the literature.
These include shock without trauma code 785.50with all subcodes (785.51,
785.52, 785.59), hypotension code 458with subcodes (458.0, 458.8 458.9),
cardiovascular failure code 427.5 and the nonspecific low blood pressure
code 796.3.
d Studies reporting 2 or more subsets,6,7,30,32 current study (whole population
and Group 1), and GiViTI database account for 52 data points from 44 studies.
See Figure 2 notes for further details.
e I2 is the percentage of between-study heterogeneity that is attributable to a
true variability in septic shockmortality, rather than sampling variation,
implying heterogeneity.
f τ2 refers to the between-study variance within groups in random-effects
meta-analysis.
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thermia(>38.3°C),hypothermia(<36°C),chillswithrigor, tachyp-
nea (>20/min), leukopenia (<4000 cells/μL), hyperglycemia
(plasmaglucose level >120mg/dL [6.7mmol/L), platelet count
<100 ×103/μL, and coagulopathy.
Figure 2. Random-EffectsMeta-analysis of Studies Identified in the Systematic Review,
Reporting Septic ShockMortality
0 80 10040 60
Mortality, % (95% CI)
20
Septic Shock
Deaths, No.Source
Consensus Definition 
Mortality, %
(95% CI)
Patients With
Septic Shock,
No.
90 125Degoricija et al,46 2006 72.0 (64.1-79.9)
41 78Angkasekwinai et al,38 2007 52.6 (41.5-63.6)
30 93Nesseler et al,27 2013 32.3 (22.8-41.8)
85 145Sakr et al,25 2013 58.6 (50.6-66.6)
418 856Goncalves-Pereira et al,23 2014 48.8 (45.5-52.2)
4146 7974Leligdowicz et al,5 2014 52.0 (50.9 -53.1)
144 319Ortiz et al,19 2014 45.1 (39.7-50.6)
Hypotension
81 159Laupland et al,47 2004 50.9 (43.2-58.7)
Hypotension + Vasopressor Therapy
129 283Rodriguez et al,31 2001 45.6 (39.8-51.4)
Hypotension + Vasopressor Therapy + Serum Lactate Level >2 mmol/L
3602 8520Group 1b 42.3 (41.2-43.3)
106 203Silva et al,48 2004 52.2 (45.3-59.1)
28 57Laupland et al,49 2005 49.1 (36.5-61.8)
Hypotension + Perfusion Abnormalities + Vasopressor Therapy
19 41Lundberg et al,54 1998 46.3 (31.1-61.6)
3428 7436Levy et al,6 2010 46.1 (45.0-47.2)
728 1495Quenot et al,26 2013 48.7 (46.2-51.2)
250 462Vincent et al,43 2006 54.1 (49.6-58.7)
90 363Karlsson et al,40 2007 24.8 (20.4-29.2)
250 462Sakr et al,39 2007 54.1 (49.6-58.7)
185 255Kauss et al,34 2010 72.5 (67.1-78.0)
915 2494Levy et al,6 2010 36.7 (34.8-38.6)
441 939Phua et al,32 2011 47.0 (44.3-49.7)
117 282Ogura et al,20 2014 41.5 (35.7-47.2)
15 935 26 295GiViTI database, 2015a 60.6 (60.0-61.2)
Hypotension or Vasopressor Therapy
14 36Dahmash et al,59 1993 38.9 (23.0-54.8)
73 101McLauchlan et al,58 1995 72.3 (63.5-81.0)
Hypotension or Serum Lactate Any Value or Vasopressor Therapy
827 2536Liu et al,21 2014 32.6 (30.8-34.4)
6556 18 840SSC database,16 2016b 34.8 (34.1-35.5)
International Classification of Diseases Codes
13 269 26 172Annane et al,51 2003 50.7 (50.1-51.3)
457 1562Flaatten,50 2004 29.3 (27.1-31.6)
117 321Whittaker et al,24 2013 36.4 (31.2-41.7)
7 12Pittet et al,57 1995 58.3 (30.4-86.2)
32 80Schoenberg et al,53 1998 40.0 (29.3-50.7)
119 190Engel et al,42 2007 62.6 (55.8-69.5)
27 59Esteban et al,41 2007 45.8 (33.1-58.5)
164 303Khwannimit and Bhuayanontachai,37 2009 54.1 (48.5-59.7)
22 61Moore et al,33 2011 36.1 (24.0-48.1)
215 530Zahar et al,30 2011 (community) 40.6 (36.3-44.8)
123 232Zahar et al,30 2011 (ICU) 53.0 (47.1-59.0)
233 580Zahar et al,30 2011 (nosocomial) 40.2 (36.1-44.2)
29 47Klein Klowenberg et al,7 2012 61.7 (47.8-75.6)
228 740Park et al,28 2012 30.8 (27.5-34.1)
Hypotension ± Vasopressor Therapy or Metabolic Abnormalities
75 324Peake et al,36 2009 23.1 (18.6-27.7)
Serum Lactate Level >4 mmol/L
242 811Levy et al,6 2010 29.8 (26.7-33.0)
219 466Phua et al,32 2011 47.0 (42.0-52.0)
44 129Gaspraovic et al,45 2006 34.1 (25.9-42.3)
15 53Shapiro et al,44 2006 28.3 (16.2-40.4)
Hypotension + Perfusion Abnormalities and/or Vasopressor Therapy
51 110Rangel-Frausto et al,56 1995 46.4 (37.0-55.7)
27 33Salvo et al,55 1995 81.8 (68.7-95.0)
752 1180Alberti et al,52 2002 63.8 (60.7-67.0)
202 458Povoa et al,35 2009 44.1 (39.6-48.7)
52 98Klein Klowenberg et al,7 2012 53.1 (43.2-62.9)
14 609 51 079Kaukonen et al,22 2014 28.6 (28.2-29.0)
Overall (I2 = 99.5%; P = .000) 46.5 (42.7-50.3)
Forty-four studies report septic
shock–associatedmortality5-7,19-59
and were included in the quantitative
synthesis using random-effects
meta-analysis. The Surviving
Sepsis Campaign (SSC) database
analyses with similar data are
reported in 2 studies6,29; therefore,
only one of these was used in the
meta-analysis reported.6 Levy et al
report 3 septic shock subsets,6
Klein Klowenberg et al report 2
(restrictive and liberal),7 Zahar et al
report 3 (community-acquired,
ICU-acquired, and nosocomial
infection–associated septic shock),30
and Phua et al report 2 groups,32
which were treated as separate
data points in themeta-analysis.
Studies under “consensus definition”
cite the Sepsis Consensus
Definitions.1,2 The categorization
used to assess heterogeneity does
not fully account for septic shock
details in individual studies.
SI conversion factor: To convert
serum lactate values to mg/dL, divide
by 0.111.
a Data obtained from GiViTI database
provided by Bertolini et al
(published 20158).
b Themortality data of Group 1
patients (new septic shock
population) and the overall
potential septic shock patient
populations (n = 18 840) described
in themanuscript from the current
study using the Surviving SSC
database are also included in the
meta-analysis. Septic shock–specific
data were obtained from Australian
& New Zealand Intensive Care
Society Adult Patient Database
(ANZICS), from a previously
published report.22 This results in
52 data points for random-effects
meta-analysis.
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These models were used to estimate acute hospital mor-
talityodds ratios (ORs) andadjustedORs formortalityper-unit
increase in the serum lactate level using continuous natural
log–transformed serum lactate level. Theoperating character-
istics (sensitivity/specificity over hospital mortality curves;
positive and negative predictive values) of different serum
lactate cutpoints (2, 3, and 4 mmol/L) were also tested using
the logistic regression model. Multiple imputations (n = 20)
were used to assess the statistical effect ofmissing serum lac-
tate values.
P < .05 (2-sided)wasconsideredstatistically significant.All
analyses were performed using Stata version 13.1 (StataCorp).
Results
Systematic Review andMeta-analysis
The systematic review identified 44 studies (166 479
patients) reporting septic shock mortality5-7,19-59 from a total
of 92 studies reporting sepsis cohorts between 1987 and
20155-7,19-107 (Figure 1; eTable 2 in the Supplement). Different
shock criteria were used for systolic blood pressure
(<90mmHg; <100mmHg; decrease >40mmHg; or decrease
>50% of baseline value if hypertensive), mean arterial
pressure (<70; <65; <60 mm Hg), serum lactate level (>4,
>2.5, >2, >1 mmol/L) and base deficit (−5 mmol/L) (Table 1;
eTable 2 in the Supplement). Temporal relationships
between resuscitation status and end points to shock diagno-
sis were seldom reported. The studies differed in the descrip-
tion of resuscitation, persistent hypotension, and in their
vasopressor definitions when using the cardiovascular
Sequential [Sepsis-related] Organ Failure Assessment (SOFA)
score categories.113 Diverse infection and organ dysfunction
codes were also used in the International Classification of
Diseases–based derivations.63,70,79,90 Variables highlighted in
Table 1 and in eTable 2 in the Supplement informed the Del-
phi survey questions.
The random-effects meta-analysis showed significant
heterogeneity in septic shock mortality (mean mortality,
46.5% [95% CI, 42.7%-50.3%], with a near 4-fold variation
from 23.0% to 81.8%; I2 = 99.5%; τ2 = 182.5; and P < .001)
(Figure 2). Statistically significant heterogeneity was also
observed in random-effects meta-analysis by clinical criteria
reported for septic shock case definition in studies (Table 2).
The meta-regression models described could not explain this
heterogeneity (eTable 3A and eTable 3B in the Supplement).
Delphi Study
In the first round, informed by the systematic review, 15 task
force members (88%) voted to include persistent hypoten-
sion, vasopressor therapy, and hyperlactatemia in the
updated criteria. There was no agreement on the lower cutoff
for serum lactate level in this round. Eleven members (65%)
voted that including fluid resuscitation would improve the
Table 2. RandomEffectsMeta-Analysis by Septic Shock Criteria Groups
Septic Shock Case Definition Criteriaa No.b
Mortality, No. of Events/
No. of Patients (%) [95% CI]c
Heterogeneity
Statisticd df P Value I2, %e τ2f
Consensus definitions cited (no description) 7 4954/9590
(51.6) [46.3-56.9]
53.2 6 <.001 88.7 39.9
Hypotension 6 15 003/51 976
(39.8) [30.1-49.5]
100.5 5 <.001 95.0 129.5
Hypotension + perfusion abnormalities and/or
vasopressor therapy
3 830/1323
(63.3) [48.3-78.4]
20.4 2 <.001 90.2 155.8
Hypotension + vasopressor therapy 11 18 446/32 095
(48.9) [40.5-57.4]
919.8 10 <.001 98.9 195.8
Hypotension + vasopressor therapy
+ serum lactate level >2 mmol/L
1 3602/8520
(42.3) [41.2-43.3]
0
Hypotension + perfusion abnormalities
+ vasopressor therapy
3 4175/8972
(47.0) [45.0-49.0]
3.4 2 .19 40.5 1.33
Hypotension ± vasopressor therapy
or metabolic abnormalities
1 75/324
(23.1) [18.6-27.7]
0
Hypotension or vasopressor therapy 13 1286/2971
(48.4) [41.3-55.5]
165.3 12 <.001 92.7 142.3
Hypotension or serum lactate any value
or vasopressor therapy
2 7383/21 376
(33.9) [31.8-36.0]
4.9 1 .03 79.4 1.9
International Classification of Diseases codes 3 13 843/28 055
(38.9) [22.5-55.2]
343.8 2 <.001 99.4 205.6
Serum lactate level >4 mmol/L 2 461/1277
(38.3) [21.5-55.1]
32.6 1 .005 96.9 142.6
Overall 52 70 058/166 479
(46.5) [42.7-50.3]
11026.7 51 <.001 99.5 182.5
Abbreviation: df, degree of freedom.
SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.
a Interpretation of the operationalization described for criteria to detect a septic
shock case in individual studies reporting septic shockmortality.
bNumber of data points from studies included in the systematic review shown
in Figure 2 (see Figure 2 legend).
c Septic shockmortality was reported by 44 studies. Four studies report septic
shock subsets6,7,30,32; data obtained from GiViTi database provided by
Bertolini et al8 and the current septic shock study resulting in 52 data points
(further information provided in Figure 2 legend).
d The categorization used to assess heterogeneity does not fully account for
septic shock details in individual studies.
e Percentage of between-study heterogeneity attributable to true variability in
septic shockmortality, rather than sampling variation, implying heterogeneity.
f τ2 refers to the between-study variance within groups in random-effects
meta-analysis.
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criteria. The task force determined that neither a severity
grading for septic shock nor criteria for either adequacy of
fluid resuscitation or persistent hypotension should be pro-
posed because of the nonstandardized use of hemodynamic
monitoring, resuscitation protocols, and vasopressor dosing
in clinical practice. (Other results are reported in eTable 4 in
the Supplement.)
InDelphi round 2, the task forcewas providedwith a pre-
liminary descriptive analysis from the SSC database. With
agreement on the description of the septic shock illness con-
cept, 3 test variables (hypotensionafter fluid resuscitation, va-
sopressor therapy, and serum lactate level)were agreedon for
predictive validity analyses. The “after fluids” field in the SSC
database was used as a proxy for resuscitation. The need for
vasopressors was agreed as a proxy for persistent hypoten-
sionby95%of the task force.Twelvemembers (71%)voted that
aminimumvasopressor dose should not be proposed in view
of the variability in blood pressure targets and resuscitation
protocols identified by the systematic review, and because of
variable sedation use. Vasopressor therapy was therefore
treated as a binary variable within the analysis. To derive an
optimal cutoff for serum lactate level, 13 task force members
(77%) agreedon acute hospitalmortality as the outcomevari-
able.The test variables couldbepresenteither aloneor in com-
binations, thus identifying6potential groups of patientswith
septic shock (Table 3; eTable 5 in the Supplement).
Prior to the final round of the Delphi process, all analyses
from the SSC data set and the EHR data sets were provided.
These findings generated thenewdefinition—“septic shock is
defined as a subset of sepsis in which underlying circulatory,
cellular, and metabolic abnormalities are associated with a
greater risk of mortality than sepsis alone”—and the clinical
criteria described below.
Cohort Studies
SSC Database
Patientswith serum lactate levels greater than4mmol/Lwho
didnot receive fluids as recommendedby theSSCguidelines111
(n = 790 [2.8%]) were excluded. Patients without any serum
lactate values measured were excluded initially for full case
analysis (n = 4419 [15.7%]) but were reassessed in the miss-
ingdata analysis.Of the22941 remainingpatients, 4101 coded
ashaving severe sepsiswere excluded fromthis analysis, gen-
erating the analysis set of 18840patientswhowere either hy-
Table 3. Distribution of Septic Shock Cohorts and CrudeMortality From Surviving Sepsis Campaign Database (n = 18 840 patients)
Cohortsa
Lactate
Category,
mmol/Lb
No. (% of total)
[n = 18 840]
Acute Hospital Mortality,
No. (%) [95% CI]
χ2 Test
for Trend
Mortality,
Adjusted OR
(95% CI)c P Valuec
Group 1 (hypotensive after fluids
and vasopressor therapy and serum lactate
levels >2 mmol/L) >2 to ≤3 2453 (13.0) 818 (33.3) [31.5-35.3] <.001 1 [Reference]
>3 to ≤4 1716 (9.1) 621 (36.2) [33.9-38.5]
>4 4351 (23.1) 2163 (49.7) [48.2-51.2]
All 8520 (45.2) 3602 (42.3) [41.2-43.3]
Group 2 (hypotensive after fluids
and vasopressor therapy and serum lactate
levels ≤2 mmol/L)
≤2 3985 (21.2) 1198 (30.1) [28.6-31.5] NAd 0.57 (0.52-0.62) <.001
Group 3 (hypotensive after fluids
and no vasopressors and serum lactate
levels >2 mmol/L) >2 to ≤3 69 (0.4) 15 (21.7) [12.7-33.3] .04 0.65 (0.47-0.90) .009
>3 to ≤4 57 (0.3) 14 (24.6) [14.1-37.8]
>4 97 (0.5) 35 (36.1) [26.6-46.5]
All 223 (1.2) 64 (28.7) [22.9-35.1]
Group 4 (serum lactate levels >2 mmol/L
and no hypotension after fluids
and no vasopressors) >2 to ≤3 860 (4.6) 179 (20.8) [18.1-23.7] <.001 0.71 (0.62-0.82) <.001
>3 to ≤4 550 (2.9) 105 (19.1) [15.9-22.6]
>4 1856 (9.9) 555 (29.9) [27.8-32.0]
All 3266 (17.3) 839 (25.7) [24.2-27.2]
Group 5 (serum lactate levels between
2-4 mmol/L and no hypotension before fluids
and no vasopressors) >2 to ≤3 1624 (8.6) 489 (30.1) [27.9-32.4] NA
d 0.77 (0.66-0.90) .001
>3 to ≤4 1072 (5.7) 313 (29.2) [26.5-32.0]
>4 790e
All 2696 (14.3) 802 (29.7) [28.0-31.5]
Group 6 (hypotensive after fluids and no
vasopressors and serum lactate ≤2 mmol/L)
≤2 150 (0.8) 28 (18.7) [12.8-25.8] NAd 0.32 (0.20-0.51) <.001
Abbreviations: NA, not available; OR, odds ratio.
SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.
a Mean arterial pressure less than 65mmHgwas used to define hypotension.
“After fluids” was defined using the field “crystalloids” coded as a binary term
within the Surviving Sepsis Campaign database.
bUsing χ2 tests, trends in mortality across serum lactate categories within
groups (>2 to3mmol/L; >3 to4mmol/L and >4mmol/L) were assessed.
c Refers to the adjusted OR generated using generalized estimating equation
regressionmodel (eTable7 in the Supplement).
d χ2 test for trend could only be performed if there were 3 or more serum
lactate categories.
e Excluded from full case analysis.
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potensive after fluids or required vasopressors or had a se-
rum lactate level measurement (Figure 3 and Table 3).
Hypotensionwas reported in83.1%, serumlactate level greater
than2mmol/L in 78.1%, and receipt of vasopressors in66.4%.
Overall, crude hospital mortality was 34.7%. Cohort charac-
teristics by setting are shown in eTable 6 in the Supplement.
Predictive Validity of Potential Septic Shock Groups
Of the6groupsofpotentialpatientswithseptic shock (Table3),
the most prevalent was group 1 (hypotension + vasopressor
therapy + serum lactate level >2mmol/L) (n = 8520); followed
by groups 2 (n = 3985) and 4 (n = 3266). Crude hospital mor-
tality rates in these 3 groupswere42.3%, 30.1%, and25.7%, re-
spectively. Statistically significant increasing trends in crude
mortalitywereobservedover increasingserumlactate levelcat-
egorieswithingroups (χ2 testof trend:P < .001 forgroups 1and
4, P = .04 for group 3). The adjusted OR for hospital mortality
using group 1 for reference was significantly lower in all other
groups (P < .01 for groups 2 to 6), suggesting that group 1 rep-
resentsadistinct subpopulationwithasignificantlygreater risk
of death (eTable 7 in the Supplement). By amajority (cumula-
tive first choice, 72.2%; second choice, 55.6%) (eTable 4 in the
Supplement), the task force agreed that group 1wasmost con-
sistent with the proposed septic shock definition, thus gener-
ating the new septic shock criteria.
Derivation of Serum Lactate Cutoff Value andMissing Data Analysis
In thegeneralizedestimatingequationmodel (shown ineTable
8 in the Supplement), serum lactate levelwas associatedwith
mortality, and the adjusted OR for hospital mortality in-
creased linearly with increasing serum lactate level. An in-
crease in serum lactate level from 2 to 10 mmol/L increased
the adjusted OR for hospital mortality from 1.4 (95% CI, 1.35-
1.45) to 3.03 (95%CI, 2.68-3.45) (referent lactate = 1;Figure4).
A serum lactate level greater than2mmol/Lwas chosenas the
preferred cutoff value for thenewseptic shock criteria, the ra-
tionale being the trade-off betweenhighest sensitivity (82.5%
when using the n = 18840 subset, and 74.9%when using pa-
tients in groups 1 and 2 combined [n = 12475]), and the deci-
sion from theDelphi process to identify the lowest serum lac-
tate level independently associatedwithagreater riskofdeath
(OR of 1.4 at a lactate value of 2 mmol/L) (Table 4; eTable 9,
eFigure 1, and eFigure 2 in the Supplement).
Predicatedonthisunderstandingof theSSCdatabasestruc-
ture and the regression analyses completed (eTable 6, eTable
7, andeTable8 in theSupplement),weassumed thatdatawere
missing at random; ie, any difference between observed val-
ues and missing values did not depend on unobserved data.
Complete case analysiswas therefore performed, followedby
multiple imputation analysis to support the missing-at-
random assumption.114 The ORs for mortality per unit in-
Figure 3. Selection of Surviving Sepsis Campaign Database Cohort
28 150 Patients identified from SSC database
23 731 With serum lactate values
4419 Excluded from full case analysis
(missing continuous serum
lactate values) a
18 840 Met potential septic shock definition groups
and included in full case analysis cohort
Group 1
8520 Patients
Hypotensive after fluids
Requires vasopressors
Serum lactate >2 mmol/L
Group 2
3985 Patients
Hypotensive after fluids
Requires vasopressors
Serum lactate ≤2 mmol/L
Group 5
2696 Patients
Not hypotensive before
fluids
Requires vasopressors
Serum lactate >2 mmol/L
Group 4
2696 Patients
Not hypotensive after
fluids
Requires no vasopressors
Serum lactate >2 mmol/L
Group 3
223 Patients
Hypotensive after fluids
Requires no vasopressors
Serum lactate >2 mmol/L
Group 6
150 Patients
Hypotensive after fluids
Requires no vasopressors
Serum lactate ≤2 mmol/L
4101 Excluded (did not meet septic
shock definition by definition groups)
22 941 Potentially eligible for full analysis set
790 Excluded (serum lactate level
>4 mmol/L and did not receive
fluids or vasopressors)
Hypotension was defined as mean arterial pressure less than 65mmHg.
Vasopressor therapy tomaintain mean arterial pressure of 65mmHg or higher
is treated as a binary variable. Serum lactate level greater than 2mmol/L (18
mg/dL) is considered abnormal. The “after fluids” field in the Surviving Sepsis
Campaign (SSC) database was considered equivalent to adequate fluid
resuscitation. “Before fluids” refers to patients who did not receive fluid
resuscitation. Serum lactate level greater than 2mmol/L after fluid resuscitation
but without hypotension or need for vasopressor therapy (group 4) is defined
as “cryptic shock.” Missing serum lactate level measurements (n = 4419 [15.7%])
and patients with serum lactate levels greater than 4mmol/L (36mg/dL) who
did not receive fluids as per SSC guidelines (n = 790 [2.8%]) were excluded
from full case analysis. Of the 22 941 patients, 4101 whowere coded as having
severe sepsis were excluded. Thus, the remaining 18 840 patients were
categorized within septic shock groups 1 to 6.
aPatients with screening serum lactate levels coded as greater than 2mmol/L
(n=3342) were included in themissing-data analysis.
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crease in serum lactate level using complete case analysis
(n = 18840) and imputed analyses (n = 22 182) were similar
(1.09 [95%CI, 1.08-1.10]; P < .001 vs 1.09 [95%CI, 1.08-1.09];
P < .001, respectively). The imputedandcomplete case analy-
sis probabilities of hospitalmortalitywere also similar (36.4%
and 35.5%, respectively).
EHRData Sets
TheUPMCandKPNCEHRs included 148907and321 380adult
patients with suspected infection, respectively (eTable 10 in
the Supplement). Forty-six percent (n = 5984) of UPMC pa-
tients and 39% (n = 54 135) of KPNC patients with 1 or more
SOFAscorepoints and suspected infection fulfilled criteria for
1 of the 6 potential septic shock groups described. Patients
meeting group 1 criteria (hypotension + vasopressor
therapy + serum lactate level >2 mmol/L) comprised 5.3%
(UPMC) and 14.9% (KPNC) of the EHR population of patients
with suspected infection andhadamortality of 54%and35%,
respectively. Similar to theSSCdatabase, crudemortality rates
within each group were higher among those with higher se-
rum lactate levels (Table 5).
Discussion
The systematic review illustrated thevariability in criteria cur-
rently used to identify septic shock, whereas the meta-
analysis demonstrated the heterogeneity in mortality. In-
formedby this systematic review, aDelphiprocesswasused to
reach a consensus definition of septic shock and related clini-
cal criteria. Three large data sets were then used to determine
the predictive validity of these criteria. Septic shock was de-
fined as a subset of sepsis in which circulatory, cellular, and
metabolicabnormalitiesareassociatedwithagreaterriskofmor-
tality than sepsis alone. The clinical criteria representing this
definitionwere theneed for vasopressor therapy tomaintain a
MAP of 65 mmHg or greater and having a serum lactate level
greater than 2mmol/L persisting after fluid resuscitation.
The proposed definition and criteria of septic shock differ
fromprior definitions1,2,111 in 2 respects: (1) the need for both a
serum lactate level and vasopressor-dependent hypotension
(ie, cardiovascular SOFA score ≥2) instead of either alone
and (2) a lower serum lactate level cutoff of 2 mmol/L vs
Figure 4. Serum Lactate Level Analysis
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Adjusted odds ratio for actual serum lactate levels for the entire septic shock
cohort (N = 18 840). The covariates used in the regressionmodel include region
(United States and Europe), location where sepsis was suspected (emergency
department, ward, or critical care unit), antibiotic administration, steroid use,
organ failures (pulmonary, renal, hepatic, and acutely alteredmental state),
infection source (pneumonia, urinary tract infection, abdominal, meningitis,
and other), hyperthermia (>38.3°C), hypothermia (<36°C), chills with rigor,
tachypnea (>20/min), leukopenia (<4000 cells/μL), hyperglycemia (plasma
glucose >120mg/dL [6.7 mmol/L]), platelet count <100 ×103/μL, and
coagulopathy (eMethods 3 in the Supplement). The adjusted odds ratio (OR)
for the 6 groups presented in eTable 7 in the Supplement and the adjusted
OR for the individual variables (lactate, vasopressor therapy, and fluids)
are reported in eTable 8 in the Supplement. To convert serum lactate values
to mg/dL, divide by 0.111.
Table 4. Characteristics of Serum Lactate Level Cutoff Values for Complete Case Analysis and Imputation Analysis Using Surviving Sepsis
Campaign Database
Characteristic
Serum Lactate Level, mmol/L
>2 >3 >4
Died/Total % (95% CI) Died/Total % (95% CI) Died/Total % (95% CI)
Complete Case Analysis (n = 18 795)
Hospital mortality, % 5757/18 795 30.6 (29.9-31.4) 6101/18 795 32.5 (31.8-33.2) 6456/18 975 34.3 (33.7-35.0)
Sensitivity, % 5372/6509 82.5 (81.6-83.4) 3779/6509 58.1 (56.8-59.3) 2811/6509 43.2 (42.0-44.4)
Specificity, % 2748/12 286 22.4 (21.6-23.1) 6418/12 286 52.2 (51.4-53.1) 8564/12 286 69.7 (68.9-70.5)
PPV, % 5372/14 910 36.0 (35.3-36.8) 3779/9647 39.2 (38.2-40.2) 2811/6533 43.0 (41.8-44.2)
NPV, % 2748/3885 70.7 (69.3-72.2) 6418/9148 70.1 (69.2-71.1) 8564/12 286 69.8 (69.0-70.7)
Imputed Missing Serum Lactate Level (n = 22 182)
Hospital mortality, % 6965/22 182 31.4 (30.8-32.0) 7363/22 182 33.2 (32.6-33.8) 7772/22 182 35.0 (34.4-35.7)
Sensitivity, % 6457/7748 83.3 (82.5-84.2) 4461/7748 57.6 (56.5-58.7) 2931/7748 37.8 (36.7-38.9)
Specificity, % 3341/14 434 23.1 (22.5-23.8) 7833/14 434 54.3 (53.5-55.1) 10 801/14 434 74.8 (74.1-75.5)
PPV, % 6457/17 550 36.8 (36.1-37.5) 4461/11 062 40.3 (39.4-41.2) 2931/6564 44.6 (43.4-45.8)
NPV, % 3341/4634 72.1 (70.8-73.4) 7833/11 120 70.4 (69.6-71.3) 10 801/15 618 69.2 (68.4-69.9)
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.
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4mmol/L as currently used in the SSC definitions. In the new
septic shockdefinition, an increase in serumlactate level ispo-
sitioned as a proxy for a cellularmetabolic abnormality, and as
a variable independently associatedwith acutemortality (pre-
dictive validity), which is consistent with the published
literature.115-118 An elevated serum lactate level is not specific
forcellulardysfunction insepsis118,119buthas facevaliditygiven
the lack of a superior yet readily available alternative. This
present study identifies a lower serum lactate level cutoff as
an independent prognostic variablewhen comparedwith a re-
cent analysis of the entire SSC database. This disparity is ex-
plained by using a data set of 18840 patients in the analysis in
this study rather than the total 28 150-patientSSCdata setused
byCasserlyetal.17Fromthis subpopulation6groupswere iden-
tified and analyzed as risk strata within the generalized esti-
matingequationmodel andperformance-tested forvarious se-
rumlactate level cutoffs. Thegroupwitha significantlygreater
risk of deathwas then selected. In contrast, Casserly et al17 re-
ported the independent relationship of hypotension and se-
rum lactate levels withmortality in severe sepsis.
The6potential septic shockpatientgroupsanalyzed in this
studyalsoprovideanexplanation for theheterogeneity in sep-
tic shockmortalityhighlightedby themeta-analysis. Depend-
ing on the group selected, septic shockmortality ranged from
12.8%to51.2%within theSSCdata set and from7.0%to64.0%
in theEHRdata sets. TheKPNCEHRdata set corroborated the
consistent trends of highermortality associatedwith ahigher
serum lactate level, even in a population with a wider range
of illness severity captured by more prevalent measurement
of serum lactate levels.
The key strengths of the present study are in themethod-
ology used to arrive at the new definition and clinical criteria
for septic shock, a clinical syndrome with a range of signs,
symptoms,andbiochemical abnormalities thatarenotpathog-
nomonic. Furthermore, the supporting studies (systematic re-
view, Delphi process, and analyses of the SSC and EHR co-
horts) were iterative and concurrent with the consensus
process, a significant step forward fromprevious definitions.
This studyalsohasseveral limitations.First, thesystematic
reviewdidnot formally assess studyquality andwas restricted
toMEDLINEpublications,adultpopulations,andobservational
studiesreportingepidemiology.Second,onlytheDelphi-derived
variables were tested inmultiple data sets to generate the pro-
posedsepticshockcriteria.Othervariables, includingtissueper-
fusionmarkers (eg,basedeficit,oliguria,acutealterationinmen-
tation), blood pressure characteristics (eg, diastolic pressure),
resuscitation end points (eg, central venous saturation, lactate
clearance),andnumerousbiomarkersreportedintheliterature,17
couldpotentially improveon theproposedseptic shockcriteria
butwerenot included.However,operationalizingthedefinition
of septic shockwith3commonlymeasuredvariables should in-
creasebothgeneralizabilityandclinicalutility.Third, the lackof
agoldstandarddiagnosticcriteriaforsepticshock8precludescom-
parative assessment of these proposed criteria. Fourth, all data
setshadmissingdata that couldpotentially introducea formof
selection bias.120 In the primary data set (SSC database) this is-
suewasaddressedbydemonstrating that full caseanalysis is an
appropriate method (see “Derivation of Serum Lactate Cutoff
ValueandMissingDataAnalysis”).Fifth,serumlactatemeasure-
mentsarenotuniversallyavailable, especiallyoutsideofacriti-
cal care setting or in resource-limited environments. Although
feasibility isaquality indicator foradefinition,8 identificationof
a critically ill patientwould generally trigger obtaining a serum
lactatemeasurement,both tostratify riskandtomonitor the re-
sponse to treatment.17 Sixth,althoughtheproposednewdefini-
tionandclinicalcriteriaforsepsisarearbitrary, thesedohavepre-
dictivevalidityformortality,alongsidefaceandcontentvalidity.8
This study represents one step in anongoing iterativepro-
cess and provides a resourceful structure and a predictive va-
lidity standard for future investigations in this area. Prospec-
tive validation of the clinical criteria may improve on the
variables and cutoffs proposed herein, and identification and
Table 5. CrudeMortality in Septic Shock Groups FromUPMC and KPNCData sets
Variablea
Highest Serum Lactate
Levels 24 h After
Infection Identified,
mmol/L
UPMC KPNC
No. (%)
(n = 5984)
Acute Hospital Mortality No. (%)
(n = 54 135)
Acute Hospital Mortality
No. % (95% CI) No. % (95% CI)
Group 1 >2 (all) 315 (5.3) 171 54.3 (48.6-59.9) 8051 (14.9) 2835 35.2 (34.2-36.3)
>3 246 (4.1) 147 59.8 (53.3-65.9) 6006 (11.1) 2355 39.2 (38.0-40.5
>4 189 (3.2) 120 63.5 (56.2-70.4) 4438 (8.2) 1939 43.7 (42.2-45.2)
Group 2 ≤2 147 (2.5) 37 25.2 (18.4-33.0) 3094 (5.7) 582 18.8 (17.4-20.2)
Group 3 >2 (all) 3544 (59.2) 1278 36.1 (34.5-37.7) 12 781 (23.6) 2120 16.6 (15.9-17.2)
>3 2492 (41.6) 1058 42.5 (40.5-44.4) 6417 (11.9) 1381 21.5 (20.5-22.5)
>4 1765 (29.5) 858 48.6 (46.3-51.0) 3316 (6.1) 914 27.6 (26.0-29.1)
Groups 4
and 5
>2 (all) 1978 (33.1) 355 17.9 (16.3-19.7) 30 209 (55.8) 2061 6.8 (6.5-7.1)
>3 1033 (17.3) 224 21.7 (19.2-24.3) 12 450 (23.0) 1138 9.1 (8.6-9.7)
>4 566 (9.4) 146 25.8 (22.2-29.6) 5394 (9.9) 637 11.8 (11.0-12.7)
Abbreviations: KPNC, Kaiser Permanente Northern California; SSC, Surviving
Sepsis Campaign; UPMC, University of PittsburghMedical Center.
SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.
a Group 1 refers to patients with hypotension + vasopressors + serum lactate
levels greater than 2mmol/L. Group 2 refers to patients with hypotension +
vasopressors + serum lactate levels less than 2mmol/L. Group 3 refers
to patients with hypotension and serum lactate levels greater than 2mmol/L.
Groups 4 and 5 refer to isolated serum lactate level greater than 2mmol/L.
Counts within a group are not mutually exclusive, as those with serum
lactate levels greater than 2mmol/L will include those in the higher serum
lactate cutoffs.
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validation of novel markers of organ dysfunction and shock
may replace lactate level.8
Conclusions
Based on a consensus process using results from a system-
atic review, surveys, and cohort studies, septic shock is
defined as a subset of sepsis in which underlying circula-
tory, cellular, and metabolic abnormalities are associated
with a greater risk of mortality than sepsis alone. Adult
patients with septic shock can be identified using the clini-
cal criteria of hypotension requiring use of vasopressors to
maintain mean blood pressure of 65 mm Hg or greater and
having a serum lactate level greater than 2 mmol/L persist-
ing after adequate fluid resuscitation.
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